Figure 3. .

Topical pazopanib reduces immunoreactive albumin in the retina of eyes injected with VEGF. Adult C57BL/6 mice were given no injection (A) or a 1 μL intraocular injection of 10⁻⁶ M VEGF (B, C), and after 6 hours they were perfused with PBS. Frozen ocular sections were stained with Griffonia simplicifolia (GSA) lectin, which stains blood vessels (green), and immunohistochemically stained for albumin (orange). A section from an uninjected eye shows some staining for albumin in the choroid, but none in the retina (A), while a section from a VEGF-injected eye shows albumin staining in the choroid and in the retina adjacent to retinal vessels (B). There was no staining when the primary antibody was eliminated (C). Another group of mice were given 10 mg/mL pazopanib eye drops in one eye and vehicle eye drops in the other eye tid for 14 days, and then given an intraocular injection of 1 μL 10⁻⁶ M VEGF in each eye. Six hours after injection, sections from pazopanib-treated eyes showed staining for albumin in the choroid, but none in the retina (D), while vehicle-treated eyes showed staining for albumin around retinal blood vessels (E). High magnification shows albumin in the wall of vessels and in surrounding retina (F).